New experimental drug CTX-8371 enters first human tests for tough cancers

NCT ID NCT06150664

Recruiting now Disease control Sponsor: Compass Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times

Summary

This early-stage study is testing an experimental drug called CTX-8371 in people with advanced lung, breast, lymphoma, head and neck, or skin cancers that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 85 participants will receive the drug by IV every two weeks. Because this is a first-in-human trial, it is too early to know if the drug will shrink tumors or improve survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CTX-8371 (an experimental drug given by IV infusion every two weeks)
What this could lead to: If this drug is safe and shows signs of shrinking tumors, it could lead to a new treatment option for people with advanced cancers that have stopped responding to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 85 participants, so the main goal is safety, not effectiveness. The drug may not work or could cause serious side effects, and it will take years before it might become available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma head and neck squamous cell carcinoma Hodgkins lymphoma melanoma non-small cell lung carcinoma Squamous Cell Carcinoma of Head and Neck triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK SQUAMOUS CELL CARCINOMA HODGKIN LYMPHOMA MALIGNANT MELANOMA NON-SMALL CELL LUNG CANCER TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

Beth Israel Deaconess Medical Center
RECRUITING

Boston, Massachusetts, 02215, United States
D&H Cancer Research Center
WITHDRAWN

Margate, Florida, 33063, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Florida Cancer Specialists - Lake Nona
RECRUITING

Orlando, Florida, 32827, United States
Florida Cancer Specialists - Sarasota
RECRUITING

Sarasota, Florida, 34236, United States
Fort Wayne Medical Oncology and Hematology
RECRUITING

Fort Wayne, Indiana, 46804, United States
Roswell Park Cancer Institute
RECRUITING

Buffalo, New York, 14263, United States
Summit Cancer Center
RECRUITING

Spokane, Washington, 99208, United States
Tennessee Oncology
RECRUITING

Nashville, Tennessee, 37203, United States
University Cancer & Blood Center
RECRUITING

Athens, Georgia, 30607, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.